Glenmark Pharmaceuticals Inc, USA, has announced plans to launch Potassium Phosphates Injection USP in multiple dosage formats in the United States beginning in March 2026. The injectable product will be available in single-dose vials containing 15 mmol phosphorus / 22 mEq potassium per 5 mL and 45 mmol phosphorus / 66 mEq potassium per 15 mL, as well as a pharmacy bulk package vial containing 150 mmol phosphorus / 220 mEq potassium per 50 mL.
The formulation is considered bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP marketed by Fresenius Kabi under NDA 212832. The upcoming launch forms part of Glenmark’s ongoing efforts to expand its injectable product portfolio and strengthen its presence within the institutional healthcare market.
According to IQVIA sales data covering the twelve-month period ending January 2026, the U.S. market for Potassium Phosphates Injection products recorded annual sales of approximately $50.7 million. Commenting on the product introduction, Marc Kikuchi, President and Business Head for North America at Glenmark, said the company continues to focus on expanding its injectable offerings within the hospital and institutional segment.
He noted that the upcoming launch supports Glenmark’s broader commitment to delivering affordable, high-quality medicines that meet the needs of patients and healthcare providers. Injectable medicines play a vital role in hospital treatment settings, and Glenmark has been steadily building a portfolio of products designed to support healthcare institutions with reliable pharmaceutical solutions. The addition of Potassium Phosphates Injection to the company’s portfolio reflects Glenmark’s strategy of strengthening its presence in complex and specialized pharmaceutical segments.
Glenmark Pharmaceuticals Ltd, the parent company of Glenmark Pharmaceuticals Inc, is a global pharmaceutical organization focused on research-driven innovation and improved patient access to medicines. The company operates 11 manufacturing facilities across four continents, supported by six research and development centres. Its commercial operations span more than 80 countries worldwide.
Glenmark’s product portfolio includes branded medicines, generic pharmaceuticals, innovative therapies, and consumer healthcare products. The company’s therapeutic focus areas include respiratory medicine, dermatology, and oncology.
Through continuous investment in scientific research, product development, and global manufacturing capabilities, Glenmark aims to deliver medicines that improve patient outcomes while maintaining affordability and accessibility. The company was ranked among the top 100 biopharmaceutical companies worldwide by pharmaceutical sales in the 2024 Scrip 100 ranking.
